The clinicopathological phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD) correlate with the allelotypes (M or V) of the polymorphic codon 129 of the human prion protein (PrP) gene and the electrophoretic mobility patterns of abnormal prion protein (PrP(Sc)). Transmission of sCJD prions to mice expressing human PrP with a heterologous genotype (referred to as cross-sequence transmission) results in prolonged incubation periods. We previously reported that cross-sequence transmission can generate a new prion strain with unique transmissibility designated as a traceback phenomenon. To verify experimentally the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into mice expressing human PrP with the 129M/M genotype. These 129M/M mice showed altered neuropathology and a novel PrP(Sc) type after a long incubation period. We then passaged the brain homogenate from the 129M/M mouse inoculated with sCJD-VV2 prions into further 129M/M or 129V/V mice. Despite cross-sequence transmission, 129V/V mice were highly susceptible to these prions compared to the 129M/M mice. The neuropathology and PrP(Sc) type of the 129V/V mice inoculated with the 129M/M mouse-passaged sCJD-VV2 prions were identical to those of the 129V/V mice inoculated with sCJD-VV2 prions. Moreover, we generated for the first time type 2 PrP(Sc)-specific antibody in addition to type 1 PrP(Sc)-specific antibody and discovered that drastic changes in the PrP(Sc) subpopulation underlie the traceback phenomenon. Here we report the first direct evidence of the traceback in prion infection. in prolonged incubation periods. We previously reported that cross-sequence transmission can generate a 6 new prion strain with unique transmissibility designated as a traceback phenomenon. To verify 7 experimentally the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into mice 8 expressing human PrP with the 129M/M genotype. These 129M/M mice showed altered 9 neuropathology and a novel PrP Sc type after a long incubation period. We then passaged the brain 10 homogenate from the 129M/M mouse inoculated with sCJD-VV2 prions into further 129M/M or 11 129V/V mice. Despite cross-sequence transmission, 129V/V mice were highly susceptible to these 12 prions compared to the 129M/M mice. The neuropathology and PrP Sc type of the 129V/V mice 13 inoculated with the 129M/M mouse-passaged sCJD-VV2 prions were identical to those of the 129V/V 14 mice inoculated with sCJD-VV2 prions. Moreover, we generated for the first time type 2 PrP Sc -specific 15 antibody in addition to type 1 PrP Sc
neuropathology and a novel PrP
Sc type after a long incubation period. We then passaged the brain 10 homogenate from the 129M/M mouse inoculated with sCJD-VV2 prions into further 129M/M or 11 129V/V mice. Despite cross-sequence transmission, 129V/V mice were highly susceptible to these 12 prions compared to the 129M/M mice. The neuropathology and PrP Sc type of the 129V/V mice 13 inoculated with the 129M/M mouse-passaged sCJD-VV2 prions were identical to those of the 129V/V 14 mice inoculated with sCJD-VV2 prions. Moreover, we generated for the first time type 2 PrP clinicopathological phenotypes of sporadic CJD (sCJD) (15) (16) (17) (18) respectively), reflecting differences in the proteinase K-cleavage site (at residues 82 and 97, respectively) 8 (15, 18) . According to this molecular typing system, sCJD can be classified into six subgroups (MM1, 9
MM2, MV1, MV2, VV1, or VV2). 10
The homology of the PrP gene between inoculated animals and the inoculum determines the 11 susceptibility to prion infection. Transmission of sCJD prions to mice expressing human PrP with a 12 non-homologous genotype (referred to as cross-sequence transmission) results in a relatively long 13 incubation period (10, 12) . Meanwhile, the cross-sequence transmission can generate a new prion strain. of dura mater graft-associated CJD (p-dCJD) (10, 13) . Furthermore, a transmission study using p-dCJD 20 prions revealed that PrP-humanized mice with the 129V/V genotype were highly susceptible to p-dCJD 21 4 prions despite cross-sequence transmission (10) . In addition, these 129V/V mice inoculated with p-dCJD 1 prions produced type 2 PrP res (10) . These findings suggest that p-dCJD could be caused by 2 cross-sequence transmission of sCJD-VV2 prions to individuals with the 129M/M genotype. We have 3 designated these phenomena as "traceback". The traceback phenomenon was discovered for the first 4 time by a transmission study using variant CJD (vCJD) prions (2). Mice expressing bovine PrP were 5 highly susceptible to vCJD prions because vCJD was caused by cross-sequence transmission of bovine 6 spongiform encephalopathy prions to human. These findings suggest that a traceback study can be a 7 powerful tool to identify the origin of prions (2, 10, 11). However, the traceback phenomenon has not 8 been verified experimentally despite the abundant circumstantial evidence described above. 9
To verify the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into PrP-humanized 10 mice with the 129M/M genotype as an experimental model of p-dCJD. Thereafter, we inoculated these 11
MM[VV2]2
Sh+ prions into PrP-humanized mice with the 129M/M or 129V/V genotype, and compared 12 the incubation period, neuropathology, and the type of PrP res in the brain. Here we report the first direct 13 evidence of the traceback in prion infection. 14 15 peptide corresponding human PrP 97-103 was used as the immunogen because the length of the 21 5 immunogen peptide is critical for the production of proteolytic cleavage site-specific polyclonal 1 antibodies (25, 26). Cysteine residues were added to the C-terminus of the each peptide and was utilized 2 for conjugation to bovine thyroglobulin via EMCS (N-(6-Maleimidocaproyloxy)succinimide) (Dojin). 3 For the initial injection, 100 μg of conjugates were emulsified in complete Freund's adjuvant and 4 subcutaneously injected into rabbits. For the boosting injections, 100 μg of conjugates were emulsified in 5 incomplete Freund's adjuvant and were subcutaneously injected on days 7, 21, 35, 49, 63, 84, and day 6 91. At day 98, the rabbits were sacrificed and sera were collected. Antibodies were purified by affinity 7 chromatography using the immunogen peptides. 
MATERIALS AND METHODS 16

Production of
Production of knock-in mice and transgenic mice 12
The production of knock-in mice expressing human PrP with 129M/M (Ki-Hu129M/M) and 13
Ki-Hu129V/V mice has been reported previously (2). Ki-Hu129M/M mice and knock-in mice 14 expressing human PrP with 129M/M and 4 octapeptide repeats (Ki-Hu129M 4R /M 4R ) were crossed with 15 transgenic mice expressing human PrP with 129M (Tg-Hu129M) and Tg-Hu129M 4R , respectively (10) . 16
The expression levels of human PrP in the brains from Tg+Ki-Hu129M/M and Tg+Ki-Hu129M 4R /M 4R 17 were 1.2X and 9.8X, respectively, the levels observed in Ki-Hu129M/M mice. 18
19
Human brain inocula 20
Brain tissues were obtained at autopsy from CJD patients after receiving informed consent for research 21 6 use. The diagnosis of CJD and the type of PrP Sc were confirmed by neuropathological examination, 1
PrP
Sc immunohistochemistry and western blotting as described (7, 27) . The genotype and the absence of 2 mutations in the open reading frame of the PrP gene were determined by sequence analysis (8) . The CJD 3 cases selected for the transmission studies were typical of the sCJD-MM1 and sCJD-VV2 subgroups. In 4 the sCJD-VV2 case (AK), the plaque-type PrP deposition in the brain and the absence of periodic 5 synchronous discharges on electroencephalogram were confirmed. More detailed information of the 6 patient was reported previously (4) . sCJD-MM1 (H3) and sCJD-VV2 (AK) showed the same 7 transmissibilities to PrP-humanized mice as those of the other sCJD-MM1 and sCJD-VV2 isolates, 8 respectively (27). 9
10
Transmission experiments 11
Human brain homogenates (10%) and mouse brain homogenates (10%) were prepared as described (9) . 12
Intracerebral transmission was performed using 20 µl of the homogenates (27). The inoculated mice 13 were sacrificed after the onset of disease, and their brains were immediately frozen or fixed in 10% 14 buffered formalin. 15 
16
Immunohistochemistry 17
Formalin-fixed mouse brains were treated with 60% formic acid for 1 hour to inactivate the infectivity 18 and embedded in paraffin. Tissue sections were pretreated by hydrolytic autoclaving before PrP 19 immunohistochemistry (7). The PrP-N antiserum was used as the primary antibody (6) . Goat-anti-rabbit 20
immunoglobulins polyclonal antibody labeled with the peroxidase-conjugated dextran polymer, 21 7 EnVision+ (DakoCytomation) was used as the secondary antibody. 1 2
Expression of Glutathione S-transferase (GST)-fusion recombinant PrP 3
The open reading frame of the human PrP gene was amplified by PCR with human DNA. The amplified 4 fragment was cloned into pBluescript plasmid (Stratagene). With the plasmid construct, N-terminally or 5 C-terminally truncated human PrP gene fragments were amplified by PCR. The primers used for the 6 amplification are shown in Table 1 . These primers introduced BamH I sites at the 5' end of the fragments 7
and Xho I sites at the 3' end of the fragments. The amplified fragments were cloned into pGEM-T Easy 8 plasmid (Promega). After digestion with BamH I and Xho I, the fragments were inserted into the BamH 9 I/Xho I sites of the expression vector pGEX-4T-1 (GE Healthcare). Escherichia coli BL21 (DE3) were 10 transformed with the pGEX-4T-1 plasmid constructs, and GST-fusion recombinant PrP fragments were 11 purified using glutathione sepharose 4B beads (GE Healthcare) according to the manufacturer's 12 instructions. GST-fusion recombinant PrP fragments were subjected to 13% SDS-PAGE and western 13 blotting. 14 15
Enzyme-linked immunosorbent assay (ELISA) 16
Synthetic peptides corresponding to human PrP 97-103 and 93-103 were used as the antigens. Plates were 17 individually coated with 50 ng/50 μl /well antigen or with 0.1% bovine serum albumin (BSA). The 18 polyclonal antibody Tohoku 2 was serially diluted and added to each well as the primary antibody. 19
Goat-anti-rabbit IgG Fab' fraction labeled with horseradish peroxidase was used as the secondary antibody. 20
The color was developed with ο-phenylenediamine. 21
Western blotting 2
PrP
Sc was extracted from mouse brains with collagenase treatment as described (5) with some 3 modifications. Samples were subjected to 13% SDS-PAGE and western blotting as described (2). The 3F4 4 monoclonal antibody (Signet Laboratories), PrP-N (Immuno-Biological Laboratories), PrP-C 5 (Immuno-Biological Laboratories), POM2, Tohoku 1, and Tohoku 2 were used as the primary antibodies. 6
Anti-mouse EnVision+ and anti-rabbit EnVision+ were used as the secondary antibodies. The signal 7 intensities of the western blots were quantified with Quantity One software using an imaging device 8
VersaDoc 5000 (Bio-Rad Laboratories). 9
10
Statistical analysis 11
Incubation times and signal intensities of PrP res bands are expressed as mean ± SEM. Sh+ prions was shortened to 309 ± 3 days (7/7). In spite 7
of cross-sequence transmission, the mean incubation time of Ki-Hu129V/V mice was much shorter than 8 that of Ki-Hu129M/M mice. Immunohistochemical analysis of the brains from Tg+Ki-Hu129M/M 9 mice inoculated with sCJD-VV2 prions showed large plaque-type PrP deposits spread throughout the 10 cerebral grey matter and thalamus ( 
4A). 10
Firstly, with these PrP res type-specific antibodies, we performed western blot analysis of the PrP res in 11 the human brain inocula used in this transmission study (Fig. 4B) . In addition to the newly generated 12 type-specific antibodies, we used the monoclonal antibody POM2, which also specifically detects type 1 13 POM2/Tohoku 1-reactive subpopulations were observed in the sCJD-VV2 brain (Fig. 4B, bar graphs) . 17
The mean signal intensities of PrP res in the sCJD-MM1 brain were assigned as 100 / mm² in each 18 experiment using 3F4, POM2, or Tohoku 1 (n = 3). In the western blot analysis using 3F4, the mean observed in the sCJD-MM1 brain (Fig. 4B, black bar) . The mean signal intensities of PrP res in the 6 sCJD-VV2 brain were assigned as 100 / mm² in each experiment using Tohoku 2 (n = 3). Ki-Hu129M/M mice inoculated with sCJD-MM1 prions and type 2 PrP res from Ki-Hu129V/V mice 14 inoculated with sCJD-VV2 prions (Fig. 4C) (10) . These PrP res were probed with type-specific antibodies 15 Tohoku 1, Tohoku 2, or POM2. The brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 16 prions contained POM2/Tohoku 1-reactive PrP res subpopulations of which the sizes were smaller than 17 those of type 1 PrP res from Ki-Hu129M/M inoculated with sCJD-MM1 prions. However, the signal 18 intensities of these POM2/Tohoku 1-reactive bands were apparently decreased compared to those 19 detected by 3F4 (Fig. 4C, bar graphs) . The mean signal intensities of PrP res from Ki-Hu129M/M mice 20 inoculated with sCJD-MM1 prions were assigned as 100 / mm² in each experiment using 3F4, POM2, 21 12 or Tohoku 1 (n = 4). In the brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 prions, the 1 mean signal intensities of 3F4-reactive PrP res bands were 154 / mm² (white bars). However, the mean 2 signal intensities of POM2/Tohoku 1-reactive PrP res bands were 34 / mm² (hatched bar) and 113 / mm² 3 (grey bar), respectively. Since the epitopes for Tohoku 1 were located more at the C-terminal compared 4 with that of POM2 (Fig. 2) , the signal intensities of Tohoku 1-reactive bands might be higher than those inoculated with sCJD-MM1 prions (Fig. 4C, black bars) . The mean signal intensities of PrP res from 10
Ki-Hu129V/V mice inoculated with sCJD-VV2 prions were assigned as 100 / mm² in each experiment 11 using Tohoku 2 (n = 4). The brains from Ki-Hu129V/V mice inoculated with sCJD-VV2 prions 12 contained small amounts of POM2/Tohoku 1-reactive subpopulations in addition to the Tohoku 13 2-reactive majority subpopulation. Thus, in the cross-sequence transmission of sCJD-VV2 prions to 14
Tg+Ki-Hu129M/M mice, POM2/Tohoku 1-reactive subpopulations were increased, whereas the 15 Tohoku 2 reactive-subpopulation was decreased. Therefore, the upward size shift from type 2 to type 16 2 Sh+ in the western blot analysis using 3F4 reflected the shift of the majority PrP res subpopulation from 17 the Tohoku 2-reactive subpopulation to the POM2/Tohoku 1-reactive subpopulation. 18
In the second passage of the brain homogenate from Tg+Ki-Hu129M/M mouse inoculated with 19 (10) . To characterize these 1 PrP res in the brains from PrP-humanized mice inoculated with p-dCJD prions, we performed western 2 blot analysis using PrP res type-specific antibodies (Fig. 5) . Since Tg+Ki-Hu129M 4R /M 4R mice were 3 already established before the Ki-Hu129M/M mice were produced, we used them in the traceback study 4 of p-dCJD or np-dCJD prions. Subsequently, we confirmed that Tg+Ki-Hu129M 4R /M 4R , 5
Ki-Hu129M/M, and Tg+Ki-Hu129M/M mice produced PrP res identical in size in the transmission 6 studies using various CJD prions (10) . POM2/Tohoku 1-reactive subpopulations existed in the brains 7 from Tg+Ki-Hu129M 4R /M 4R mice inoculated with p-dCJD prions, but the signal intensities were 8 apparently decreased compared to those detected by 3F4 (Fig. 5, bar graphs) . The mean signal intensities 9 of PrP res from Tg+Ki-Hu129M 4R /M 4R mice inoculated with sCJD-MM1 prions were assigned as 100 / 10 mm² in each experiment using 3F4, POM2, or Tohoku 1 (n = 3). In the brains from 11
Tg+Ki-Hu129M 4R /M 4R mice inoculated with p-dCJD prions, the mean signal intensities of 3F4-reactive 12 PrP res bands were 105 / mm² (white bars). However, the mean signal intensities of POM2/Tohoku 13 1-reactive PrP res bands were 23 / mm² (hatched bar) and 45 / mm² (grey bar), respectively. The sizes of 14 POM2/Tohoku 1-reactive bands were smaller than those of type 1 PrP res from Tg+Ki-Hu129M 4R /M 4R 15 mice inoculated with non-plaque-type of dCJD (np-dCJD) prions or sCJD-MM1 prions. In addition, 16 trace amounts of the Tohoku 2-reactive subpopulation were observed in the brains from 17
Tg+Ki-Hu129M 4R /M 4R mice inoculated with p-dCJD prions, np-dCJD prions, or sCJD-MM1 prions 18 (Fig. 5, black bars) . The mean signal intensities of PrP res from Ki-Hu129V/V mice inoculated with 19 sCJD-VV2 prions were assigned as 100 / mm² in each experiment using Tohoku 2 (n = 3). Since the 20 sizes of these Tohoku 2-reactive bands were identical to those of type 2 PrP res from Ki-Hu129V/V mice 21 15 inoculated with sCJD-VV2 prions, Tohoku 2 could specifically detect type 2 PrP res . Meanwhile, in the 1 transmission of p-dCJD prions to Ki-Hu129V/V mice, POM2/Tohoku 1-reactive subpopulations were 2 decreased, whereas the Tohoku 2 reactive-subpopulation predominated. In the brains from 3
Ki-Hu129V/V mice inoculated with p-dCJD prions, the mean signal intensities of 3F4, POM2, and 4 Tohoku 1-reactive PrP res bands were 65 / mm² (white bars), 12 / mm² (hatched bar), and 13 / mm² (grey 5 bar), respectively, whereas the mean signal intensities of Tohoku 2-reactive PrP res bands were 45 / mm² 6 (black bar). Thus, the changes in PrP res subpopulation observed in this traceback study of p-dCJD prions 7
were identical to those observed in the traceback study of MM[VV2]2 Sh+ prions. 8
9
DISCUSSION 10
In order to protect humans and animals from infectious diseases, it is often crucial to determine the origin 11 of those isolates that may lie at the origin of epidemics. In the case of conventional pathogens, this is 12 relatively simple and primarily involves the sequencing of pathogen-associated nucleic acids. Because 13 prions lack informational nucleic acids, however, the unambiguous assignment of a given infection to a 14 specific source is very often impossible. Therefore, methods aimed at characterizing stable prion 15 properties after passaging through hosts would be extremely valuable. 16
Here we demonstrate the first direct evidence of traceback in prion infection. Ki-Hu129V/V mice 17 were highly susceptible to the Tg+Ki-Hu129M/M mouse-passaged sCJD-VV2 prions (MM[VV2]2 Sh+ 18 prions) despite cross-sequence transmission (Fig. 6) The present study clearly shows that traceback studies can be a reliable tool to identify the origin of 5 prions if atypical prion strains emerge through cross-sequence transmission. Although the numbers of 6 animals and human brain inocula used for the transmission were limited in the present study, we 7 demonstrated experimentally the traceback phenomenon: Ki-Hu129V/V mice were highly susceptible 8
Sh+ prions that originated from sCJD-VV2 prions. In the cross-sequence transmission of 9 sCJD-VV2 prions to Tg+Ki-Hu129M/M mice, POM2/Tohoku 1-reactive subpopulations were 10 increased, whereas the Tohoku 2 reactive-subpopulation was decreased. By contrast, the altered 11 proportion of PrP res subpopulations reverted to the original proportion through the traceback transmission 12 to Ki-Hu129V/V mice. Similar changes in the PrP res subpopulations were observed in the traceback 13 transmission of p-dCJD prions to Ki-Hu129V/V mice. Therefore, the present study shows again that 14 p-dCJD could be caused by cross-sequence transmission of sCJD-VV2 prions to individuals with the 15
129M/M genotype. 16
The drastic changes in the PrP res subpopulations can be the molecular basis of the traceback 17 phenomena. We suppose that the subpopulation change observed in the cross-sequence transmission is 18 due to adaptation and/or a selection process (3, 20) , which requires a relatively long incubation period. 19
By contrast, the subpopulation change observed in the traceback transmission might be due to 20 reemergence of the parental prions. Since the emerging prion strain generated by the cross-sequence 21 transmission retains the memory of the parental prions within its conformational properties or repertoire 1 of PrP Sc subpopulations, the parental PrP Sc subpopulation reemerges and becomes predominant if the 2 emerging prion strain is transmitted to the original host. Therefore, the incubation period can be 3 shortened, and the altered disease phenotypes revert to the original ones in traceback transmission. subpopulations can be detected in the same brain. Therefore, the significance of the conventional 18 molecular typing system using antibodies that react with all PrP res types is likely to continue to be used in 19 the classification of sCJD. 20
In conclusion, we verified experimentally that traceback studies can be a reliable tool to identify the 21 19 origin of prions. The present study shows that the changes in PrP res subpopulations correlate with the 1 changes in prion strain-specific properties, e.g., transmissibility and disease phenotypes, in the traceback 2 transmission. Hereafter, the proportion of PrP res subpopulations in human CJD cases should be analyzed 3 quantitatively using PrP res type-specific antibodies, Tohoku 1 and Tohoku 2. Incubation period in days ± SEM (n/n 0 ) a Table 2 Transmission of sCJD prions to humanized mice with 129M/M or 129V/V at Universitaet Zuerich on January 28, 2010
